@article{2040a7df4edc45699aaeaedb880662b9,
title = "Brivaracetam for the treatment of refractory epilepsy in patients with prior exposure to levetiracetam: A retrospective outcome analysis",
keywords = "ADJUNCTIVE BRIVARACETAM, ADULTS, Anti-epileptic drug, Behaviour, Brivaracetam, DOUBLE-BLIND, EFFICACY, GLYCINE, Levetiracetam, PARTIAL-ONSET SEIZURES, PHASE-III, TOLERABILITY, Treatment-emergent adverse events",
author = "Anniko Snoeren and Majoie, {Marian H J M} and Fasen, {Koen C F M} and Ijff, {Dominique M}",
note = "Copyright {\textcopyright} 2022. Published by Elsevier Ltd.",
year = "2022",
month = mar,
doi = "10.1016/j.seizure.2022.02.007",
language = "English",
volume = "96",
pages = "102--107",
journal = "SEIZURE-EUROPEAN JOURNAL OF EPILEPSY",
issn = "1059-1311",
publisher = "Elsevier Saunders",
}